HIM
VNDA icon

Hillsdale Investment Management’s Vanda Pharmaceuticals VNDA Stock Holding History

Hillsdale Investment Management’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-232,642
Closed -$1.53M – 655
2023
Q2 		$1.53M Buy
+232,642
New +$1.49M 0.14% 179
2019
Q1 		– Sell
-17,400
Closed -$455K – 691
2018
Q4 		$455K Buy
+17,400
New +$409K 0.05% 262

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Hillsdale Investment Management's VNDA Position: Q3 2023 in Review

Hillsdale Investment Management sold out of Vanda Pharmaceuticals (VNDA) in Q3 2023, closing a stake of 232,642 shares — an estimated $1.53M sold.

Hillsdale Investment Management first reported a position in VNDA in Q4 2018 and held it in 2 quarters. The position peaked at $1.53M in Q2 2023. 179 funds tracked by Wall St. Rank hold VNDA as of Q3 2023.

  • Hillsdale Investment Management reported no remaining Vanda Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Hillsdale Investment Management sold 232,642 Vanda Pharmaceuticals shares in Q3 2023, an estimated $1.53M.
  • Hillsdale Investment Management first reported a position in Vanda Pharmaceuticals in Q4 2018 and held it in 2 quarters.
  • Hillsdale Investment Management's Vanda Pharmaceuticals position peaked at $1.53M in Q2 2023.
  • 179 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q3 2023.

Based on Hillsdale Investment Management's 13F filing for Q3 2023, filed 9 Nov 2023.